Pangaea Oncology, S.A. (PANG.MC)
EUR 1.68
(0.0%)
EUR 1.68
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 7.99 Million | 4.36 Million | 4.6 Million | 4.09 Million | 3.31 Million | 3.05 Million |
| Cost of Revenue | 244.85 Thousand | 255.53 Thousand | -568.61 Thousand | -512.72 Thousand | -1.09 Million | -1.23 Million |
| Gross Profit | 7.75 Million | 4.11 Million | 5.17 Million | 4.61 Million | 4.4 Million | 4.29 Million |
| Operating Expenses | 11.37 Million | 6.3 Million | 5.46 Million | 6.27 Million | 6.7 Million | 6.23 Million |
| Selling, General and Administrative Expenses | 9.34 Million | 1.27 Million | 786.85 Thousand | 1.2 Million | 1.24 Million | 1.39 Million |
| Research and Development Expenses | 1.02 Million | - | - | - | - | - |
| Other Expenses | 4.47 Million | - | - | - | - | - |
| Cost and Expenses | 13.77 Million | 6.56 Million | 4.9 Million | 5.76 Million | 5.61 Million | 5 Million |
| Operating Income | -3.82 Million | 2.55 Million | -532.96 Thousand | -1.66 Million | -4.79 Million | -1.78 Million |
| Interest Expense | 133.94 Thousand | 189.41 Thousand | 252.91 Thousand | 186.03 Thousand | 190.78 Thousand | 346.78 Thousand |
| Income Tax Expense | 1.28 Million | -114.71 Thousand | -456.5 Thousand | -112.68 Thousand | -143.87 Thousand | -875.71 Thousand |
| Earnings before Tax | -3.5 Million | -2.83 Million | -1.09 Million | -1.9 Million | -4.98 Million | -2.12 Million |
| Net Income | -4.65 Million | -2.71 Million | -641.9 Thousand | -1.79 Million | -4.84 Million | -1.25 Million |
| Earnings Per Share Basic | -0.15 | -0.09 | -0.03 | -0.09 | -0.28 | -0.09 |
| Earnings Per Share Diluted | -0.15 | -0.09 | -0.03 | -0.09 | -0.28 | -0.09 |
| Weighted Average Shares Outstanding | 30.14 Million | 30.44 Million | 22.81 Million | 19 Million | 17.13 Million | 13.3 Million |
| Weighted Average Shares Outstanding (Diluted) | 30.14 Million | 30.44 Million | 22.81 Million | 19 Million | 17.13 Million | 13.3 Million |
| Gross Margin | 0.97 | 0.94 | 1.12 | 1.13 | 1.33 | 1.40 |
| EBIT Margin | -0.19 | -0.27 | 0.08 | 0.17 | 0.24 | 0.19 |
| Profit Margin | -0.58 | -0.62 | -0.14 | -0.44 | -1.46 | -0.41 |
| EBITDA | -1.55 Million | -1.4 Million | 146.78 Thousand | 730.31 Thousand | -1.71 Million | 739.84 Thousand |
| Earnings Before Tax Margin | -0.48 | 0.59 | -0.12 | -0.41 | -1.45 | -0.58 |
| Breakdown | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 FY |
|---|---|---|---|---|---|---|
| Revenue | 3.23 Million | 7.99 Million | 3.23 Million | 1.73 Million | 1.73 Million | 4.36 Million |
| Cost of Revenue | 709.8 Thousand | 244.85 Thousand | 709.8 Thousand | 488.6 Thousand | 488.6 Thousand | 255.53 Thousand |
| Gross Profit | 2.52 Million | 7.75 Million | 2.52 Million | 1.25 Million | 1.25 Million | 4.11 Million |
| Operating Expenses | 3.88 Million | 10.49 Million | 3.88 Million | 1.8 Million | 1.8 Million | 6.3 Million |
| Selling, General and Administrative Expenses | 3.06 Million | - | 3.06 Million | 1.61 Million | 1.61 Million | - |
| Research and Development Expenses | 56.85 Thousand | - | 56.85 Thousand | 457 Thousand | 457 Thousand | - |
| Other Expenses | 759.46 Thousand | - | 759.46 Thousand | -258.08 Thousand | -258.08 Thousand | - |
| Cost and Expenses | 4.58 Million | 10.74 Million | 4.58 Million | 2.29 Million | 2.29 Million | 6.56 Million |
| Operating Income | -1.35 Million | -2.89 Million | -1.35 Million | -558.63 Thousand | -558.63 Thousand | 2.55 Million |
| Interest Expense | - | 133.94 Thousand | - | - | - | 189.41 Thousand |
| Income Tax Expense | 661.5 Thousand | 1.28 Million | 661.5 Thousand | 18.15 Thousand | 18.15 Thousand | -114.71 Thousand |
| Earnings before Tax | -1.25 Million | -3.5 Million | -1.25 Million | -497.93 Thousand | -497.93 Thousand | -2.83 Million |
| Net Income | -1.86 Million | -4.65 Million | -1.86 Million | -459.78 Thousand | -459.78 Thousand | -2.71 Million |
| Earnings Per Share Basic | -0.06 | - | -0.06 | -0.02 | -0.02 | - |
| Earnings Per Share Diluted | -0.06 | - | -0.06 | -0.02 | -0.02 | - |
| Weighted Average Shares Outstanding | 30.14 Million | - | 30.14 Million | 29.44 Million | 29.44 Million | 30.44 Million |
| Weighted Average Shares Outstanding (Diluted) | 30.14 Million | - | 30.14 Million | 29.44 Million | 29.44 Million | 30.44 Million |
| Gross Margin | 0.78 | 0.97 | 0.78 | 0.72 | 0.72 | 0.94 |
| EBIT Margin | -0.26 | - | -0.26 | -0.29 | -0.29 | - |
| Profit Margin | -0.58 | -0.58 | -0.58 | -0.26 | -0.26 | -0.62 |
| EBITDA | -849.91 Thousand | - | -849.91 Thousand | -497.29 Thousand | -497.29 Thousand | - |
| Earnings Before Tax Margin | -0.42 | -0.36 | -0.42 | -0.32 | -0.32 | 0.59 |
ATH-PA
603055
007810
HRMNYCP
3221
ASTRAZEN